Your browser doesn't support javascript.
loading
Chronic myeloid leukaemia: Biology and therapy.
Wang, Yun; Liang, Zhi-Jian; Gale, Robert Peter; Liao, Hua-Ze; Ma, Jun; Gong, Tie-Jun; Shao, Ying-Qi; Liang, Yang.
Afiliación
  • Wang Y; Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Liang ZJ; Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Gale RP; Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, Lo
  • Liao HZ; Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China.
  • Ma J; Harbin Institute of Hematology and Oncology, Harbin First Hospital, Harbin 150010, China.
  • Gong TJ; Harbin Institute of Hematology and Oncology, Harbin First Hospital, Harbin 150010, China. Electronic address: gongtiejun678@163.com.
  • Shao YQ; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China. Electronic
  • Liang Y; Department of Hematologic Oncology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Centre for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510060, China; State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood D
Blood Rev ; 65: 101196, 2024 May.
Article en En | MEDLINE | ID: mdl-38604819
ABSTRACT
Chronic myeloid leukaemia (CML) is caused by BCRABL1. Tyrosine kinase-inhibitors (TKIs) are the initial therapy. Several organizations have reported milestones to evaluate response to initial TKI-therapy and suggest when a change of TKI should be considered. Achieving treatment-free remission (TFR) is increasingly recognized as the optimal therapy goal. Which TKI is the best initial therapy for which persons and what depth and duration of molecular remission is needed to achieve TFR are controversial. In this review we discuss these issues and suggest future research directions.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Inhibidores de Proteínas Quinasas Límite: Humans Idioma: En Revista: Blood Rev Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Mielógena Crónica BCR-ABL Positiva / Inhibidores de Proteínas Quinasas Límite: Humans Idioma: En Revista: Blood Rev Asunto de la revista: HEMATOLOGIA Año: 2024 Tipo del documento: Article País de afiliación: China